

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076
 Estimated average burden hours per response: 4.00

1. Issuer's Identity

| | | |
|---|--|---|
| CIK (Filer ID Number) 0001107421 | Previous Names None EASYWEB INC | Entity Type X Corporation Limited Partnership Limited Liability Company General Partnership Business Trust Other (Specify) |
| Name of Issuer ZIOPHARM ONCOLOGY INC | | |
| Jurisdiction of Incorporation/Organization DELAWARE | | |
| Year of Incorporation/Organization X Over Five Years Ago Within Last Five Years (Specify Year) Yet to Be Formed | | |

2. Principal Place of Business and Contact Information

| | | | |
|--|--|--|---|
| Name of Issuer ZIOPHARM ONCOLOGY INC | | | |
| Street Address 1 ONE FIRST AVENUE | | Street Address 2 PARRIS BUILDING 34, NAVY YARD PLAZA | |
| City BOSTON | State/Province/Country MASSACHUSETTS | ZIP/PostalCode 02129 | Phone Number of Issuer 617-259-1970 |

3. Related Persons

| | | |
|--|---|--------------------------------|
| Last Name Cooper | First Name Laurence | Middle Name J.N. |
| Street Address 1 c/o Ziopharm Oncology, Inc. | Street Address 2 One First Ave. Parris Bldg 34, Navy Yard | |
| City Boston | State/Province/Country MASSACHUSETTS | ZIP/PostalCode 02129 |
| Relationship: X Executive Officer X Director Promoter | | |

Clarification of Response (if Necessary):

| | | |
|--|---|--------------------------------|
| Last Name Lafond | First Name Kevin | Middle Name G. |
| Street Address 1 c/o Ziopharm Oncology, Inc. | Street Address 2 One First Ave. Parris Bldg 34, Navy Yard | |
| City Boston | State/Province/Country MASSACHUSETTS | ZIP/PostalCode 02129 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|--|----------------|
| Hadfield | Robert | |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|--|----------------|
| Mauney | David | M. |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|--|----------------|
| Buck | Jill | |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|--|----------------|
| De Groot | Eleanor | |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|--|----------------|
| Shukla | Sath | |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|-----------------------------|--|----------------|
| Hagen | Heidi | |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|-----------------------------|--|----------------|
| Braunstein | Scott | |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|-----------------------------|--|----------------|
| Ezickson | Elan | Z. |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|-----------------------------|--|----------------|
| Pagan | Douglas | W. |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|-----------------------------|--|----------------|
| Tarriff | Scott | |
| Street Address 1 | Street Address 2 | |
| c/o Ziopharm Oncology, Inc. | One First Ave. Parris Bldg 34, Navy Yard | |
| City | State/Province/Country | ZIP/PostalCode |
| Boston | MASSACHUSETTS | 02129 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

Agriculture
 Banking & Financial Services
 Commercial Banking
 Insurance
 Investing
 Investment Banking
 Pooled Investment Fund
 Is the issuer registered as an investment company under the Investment Company Act of 1940?
 Yes No
 Other Banking & Financial Services
 Business Services
 Energy
 Coal Mining
 Electric Utilities
 Energy Conservation
 Environmental Services
 Oil & Gas
 Other Energy

Health Care
 X Biotechnology
 Health Insurance
 Hospitals & Physicians
 Pharmaceuticals
 Other Health Care
 Manufacturing
 Real Estate
 Commercial
 Construction
 REITS & Finance
 Residential
 Other Real Estate

Retailing
 Restaurants
 Technology
 Computers
 Telecommunications
 Other Technology
 Travel
 Airlines & Airports
 Lodging & Conventions
 Tourism & Travel Services
 Other Travel
 Other

5. Issuer Size

| Revenue Range | OR | Aggregate Net Asset Value Range |
|------------------------------|-----------|--|
| No Revenues | | No Aggregate Net Asset Value |
| \$1 - \$1,000,000 | | \$1 - \$5,000,000 |
| \$1,000,001 - \$5,000,000 | | \$5,000,001 - \$25,000,000 |
| \$5,000,001 - \$25,000,000 | | \$25,000,001 - \$50,000,000 |
| \$25,000,001 - \$100,000,000 | | \$50,000,001 - \$100,000,000 |
| Over \$100,000,000 | | Over \$100,000,000 |
| X Decline to Disclose | | Decline to Disclose |
| Not Applicable | | Not Applicable |

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

| | Investment Company Act Section 3(c) | |
|---|-------------------------------------|------------------|
| Rule 504(b)(1) (not (i), (ii) or (iii)) | Section 3(c)(1) | Section 3(c)(9) |
| Rule 504 (b)(1)(i) | Section 3(c)(2) | Section 3(c)(10) |
| Rule 504 (b)(1)(ii) | Section 3(c)(3) | Section 3(c)(11) |
| Rule 504 (b)(1)(iii) | Section 3(c)(4) | Section 3(c)(12) |
| X Rule 506(b) | Section 3(c)(5) | Section 3(c)(13) |
| Rule 506(c) | Section 3(c)(6) | Section 3(c)(14) |
| Securities Act Section 4(a)(5) | Section 3(c)(7) | |

7. Type of Filing

X New Notice Date of First Sale 2019-09-12 First Sale Yet to Occur
 Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes No

9. Type(s) of Securities Offered (select all that apply)

- Equity
- Debt
- Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
- Pooled Investment Fund Interests
- Tenant-in-Common Securities
- Mineral Property Securities
- Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

| | | |
|--|---|-----------------|
| Recipient | Recipient CRD Number <input checked="" type="checkbox"/> None | |
| (Associated) Broker or Dealer <input checked="" type="checkbox"/> None | (Associated) Broker or Dealer CRD Number <input checked="" type="checkbox"/> None | |
| Street Address 1 | Street Address 2 | |
| City | State/Province/Country | ZIP/Postal Code |
| State(s) of Solicitation (select all that apply) | All States | Foreign/non-US |
| Check "All States" or check individual States | | |

13. Offering and Sales Amounts

Total Offering Amount \$19,515,153 USD or Indefinite

Total Amount Sold \$19,515,153 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

Consists of amounts which may be received by the Company upon the exercise of warrant (assuming no cashless exercises)

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer | Signature | Name of Signer | Title | Date |
|-----------------------|---------------------|-----------------|-----------------------------|------------|
| ZIOPHARM ONCOLOGY INC | /s/ Robert Hadfield | Robert Hadfield | General Counsel & Secretary | 2019-09-17 |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
